EB-160

N/A

Report date: 2024/12/16 16:57:56
NME

Base Information

Drug NameEB-160
Drug Alias NameEB-160
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionKRAS G12C inhibitors
TargetsKRAS G12C
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesShanghai Euregen Biopharma Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShanghai Euregen Biopharma Co LtdZhongshan Youli Biological Medicine Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A